PMID- 38022240 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231201 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 10 DP - 2023 Oct TI - Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia. PG - e47778 LID - 10.7759/cureus.47778 [doi] LID - e47778 AB - OBJECTIVE: This study aimed to investigate and assess whether IV iron improves symptoms of chronic heart failure (CHF) in patients with iron deficiency anemia (IDA). METHOD: A total of 66 subjects with heart failure (HF) seeking therapy in the Department of Medicine's Inpatient Department (IPD) and Outpatient Department (OPD) were included. The data were collected during an outpatient or inpatient visit, documented in a predesigned and pretested proforma and then evaluated. All subjects received history-taking, examinations and regular laboratory tests after being informed and signing an agreement. On admission, the following data was collected: name, age, gender and comorbidities. The examination of subjects included a general examination and a systematic examination. Hematological parameters including hemoglobin (Haemometer, Top Tech Bio Medicals Mumbai), serum iron (Roche Cobas c501, USA), total iron binding capacity (TIBC, Beckman Coulter AU480, India), transferrin saturation percentage (TSAT% = (serum iron/TIBC) x 100), left ventricular ejection fraction (LVEF, 2D echocardiography, Nivan Healthcare Solutions, India) and ferritin (Abbott Architect Ferritin Assay, Delhi) are also important. Other blood tests like liver and renal function tests include an electrocardiogram (12-lead ECG) and two-dimensional echocardiography on admission and follow-up. RESULTS: In our study, 66 patients in total received IV iron as a treatment option to improve the symptoms of CHF with IDA; the New York Heart Association (NYHA) classification showed significant improvement (p-value <0.001). Before the intervention, 57.58% of patients had NYHA class II and 42.4% of patients had NYHA class III. After treatment, 33.33% of patients showed NYHA class II and 19.70% of patients showed NYHA class III. After iron therapy treatment, out of 29 cases of NYHA class III, nine (31.03%) cases converted to NYHA class I, seven (24.14%) cases converted to NYHA class II, and 13 (44.83%) cases belonged to the same NYHA class. Out of 37 cases of NYHA class II, 22 (59.45%) cases converted to NYHA class I, and 15 (40.54%) cases belong to the same NYHA class. CONCLUSION: Thus, we come to the conclusion that the NYHA classification has exhibited notable enhancement subsequent to the administration of parenteral iron therapy. Sufficient evidence exists to substantiate the advantageous effects of intravenous iron therapy in the treatment of iron deficiency anemia. The administration of iron therapy has been observed to yield favorable outcomes in the mitigation of symptoms among individuals afflicted with cardiac insufficiency. CI - Copyright (c) 2023, Gosavi et al. FAU - Gosavi, Rohit AU - Gosavi R AD - Department of Medicine, Krishna Vishwa Vidyapeeth, Karad, IND. FAU - Jadhav, Nitin B AU - Jadhav NB AD - Department of Medicine, Krishna Vishwa Vidyapeeth, Karad, IND. FAU - Nashte, Abhijeet AU - Nashte A AD - Department of Medicine, Krishna Vishwa Vidyapeeth, Karad, IND. LA - eng PT - Journal Article DEP - 20231027 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10676512 OTO - NOTNLM OT - chronic heart failure OT - coronary heart disease OT - erythropoiesis-stimulating agents OT - heart failure OT - hemoglobin levels OT - inflammatory cytokines OT - iron deficiency OT - true anemia COIS- The authors have declared that no competing interests exist. EDAT- 2023/11/29 18:42 MHDA- 2023/11/29 18:43 PMCR- 2023/10/27 CRDT- 2023/11/29 15:19 PHST- 2023/08/24 00:00 [received] PHST- 2023/10/24 00:00 [accepted] PHST- 2023/11/29 18:43 [medline] PHST- 2023/11/29 18:42 [pubmed] PHST- 2023/11/29 15:19 [entrez] PHST- 2023/10/27 00:00 [pmc-release] AID - 10.7759/cureus.47778 [doi] PST - epublish SO - Cureus. 2023 Oct 27;15(10):e47778. doi: 10.7759/cureus.47778. eCollection 2023 Oct.